Centre du Cancer Lausanne - Publications 2003




Home < Centre de recherche < Publications 2010 < Publications 2003

Publications 2010

Publications 2009

Publications 2008

Publications 2007

Publications 2006

Publications 2005

Publications 2004

	Publications 2003

Publications 2002

Publications 2001

Info.onco@chuv.ch

Publications : 2003
1:	Ayyoub, M., A. Zippelius, M. J. Pittet, D. Rimoldi, D. Valmori, J. C. Cerottini, P. Romero, F. Lejeune, D. Lienard and D. E. Speiser (2003).
		Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. Clin Cancer Res 9(2): 669-77.
2:	Betticher, D. C., S. F. Hsu Schmitz, M. Totsch, E. Hansen, C. Joss, C. von Briel, R. A. Schmid, M. Pless, J. Habicht, A. D. Roth, A. Spiliopoulos, R. Stahel, W. Weder, R. Stupp, F. Egli, M. Furrer, H. Honegger, M. Wernli, T. Cerny and H. B. Ris (2003).
		Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 21(9): 1752-9.
3:	Bezzi, M., M. Hasmim, G. Bieler, O. Dormond and C. Ruegg (2003).
		Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem 278(44): 43603-14.
4:	Briasoulis, E., N. Pavlidis, C. Terret, J. Bauer, W. Fiedler, P. Schoffski, J. L. Raoul, D. Hess, R. Selvais, D. Lacombe, P. Bachmann and P. Fumoleau (2003).
		Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group. Eur J Cancer 39(16): 2334-40.
5:	Christoforidis, D., P. G. Chassot, F. Mosimann, D. Lienard, F. Brunstein, D. Bejko, F. J. Lejeune and R. Chiolero (2003).
		Isolated limb perfusion: distinct tourniquet and tumor necrosis factor effects on the early hemodynamic response. Arch Surg 138(1): 17-25.
6:	D'Addario, G., A. Dieterle, J. Torhorst, R. Maibach, R. Stahel, F. Egli, A. Lohri, F. Cavalli, M. Fey, N. Ketterer and T. Cerny (2003).
		HIV-testing and newly-diagnosed malignant lymphomas. The SAKK 96/90 registration study. Leuk Lymphoma 44(1): 133-8.
7:	Dietrich, P. Y., F. A. Le Gal, V. Dutoit, M. J. Pittet, L. Trautman, A. Zippelius, I. Cognet, V. Widmer, P. R. Walker, O. Michielin, P. Guillaume, T. Connerotte, F. Jotereau, P. G. Coulie, P. Romero, J. C. Cerottini, M. Bonneville and D. Valmori (2003).
		Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen. J Immunol 170(10): 5103-9.
8:	Dormond, O. and C. Ruegg (2003).
		Regulation of endothelial cell integrin function and angiogenesis by COX-2, cAMP and Protein Kinase A. Thromb Haemost 90(4): 577-85
9:	Dormond, O., F. J. Lejeune and C. Ruegg (2002).
		Modulation of cdk2, cyclin D1, p16INK4a, p21WAF and p27Kip1 expression in endothelial cells by TNF/IFN gamma. Anticancer Res 22(6A): 3159-63.
10:	Doucey, M. A., D. F. Legler, M. Faroudi, N. Boucheron, P. Baumgaertner, D. Naeher, M. Cebecauer, D. Hudrisier, C. Ruegg, E. Palmer, S. Valitutti, C. Bron and I. F. Luescher (2003).
		The beta1 and beta3 integrins promote T cell receptor-mediated cytotoxic T lymphocyte activation. J Biol Chem 278(29): 26983-91.
11:	Gagnoux-Palacios, L., M. Dans, W. van't Hof, A. Mariotti, A. Pepe, G. Meneguzzi, M. D. Resh and F. G. Giancotti (2003).
		Compartmentalization of integrin alpha6beta4 signaling in lipid rafts. J Cell Biol 162(7): 1189-96.
12:	Godard, S., G. Getz, M. Delorenzi, P. Farmer, H. Kobayashi, I. Desbaillets, M. Nozaki, A. C. Diserens, M. F. Hamou, P. Y. Dietrich, L. Regli, R. C. Janzer, P. Bucher, R. Stupp, N. de Tribolet, E. Domany and M. E. Hegi (2003).
		Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 63(20): 6613-25.
13:	Hequet, O., G. Salles, N. Ketterer, D. Espinouse, C. Dumontet, C. Thieblemont, P. Arnaud, F. Bouafia and B. Coiffier (2003).
		Autoimmune thrombocytopenic purpura after autologous stem cell transplantation. Bone Marrow Transplant 32(1): 89-95.
14:	Karanikas, V., C. Lurquin, D. Colau, N. van Baren, C. De Smet, B. Lethe, T. Connerotte, V. Corbiere, M. A. Demoitie, D. Lienard, B. Dreno, T. Velu, T. Boon and P. G. Coulie (2003).
		Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant Canarypox virus. J Immunol 171(9): 4898-904.
15:	Mirimanoff, R. O. and R. Stupp (2003).
		Radiotherapy in low-grade gliomas: Cons. Semin Oncol 30(6 Suppl 19): 34-8.
16:	Prior, J. O., G. Barghouth, J. F. Delaloye, S. Leyvraz and A. Bischof Delaloye (2003).
		The value of bone marrow scintigraphy using 99mTc monoclonal antigranulocyte antibodies in complement to bone scintigraphy in detecting bone metastases from primary breast cancer. Nucl Med Commun 24(1): 29-36.
17:	Rimoldi, D., R. Lemoine, A. M. Kurt, S. Salvi, M. Berset, M. Matter, B. Roche, J. P. Cerottini, D. Guggisberg, J. Krischer, R. Braun, J. P. Willi, C. Antonescu, D. Slosman, F. J. Lejeune and D. Lienard (2003).
		Detection of micrometastases in sentinel lymph nodes from melanoma patients: direct comparison of multimarker molecular and immunopathological methods. Melanoma Res 13(5): 511-20.
18:	Rimoldi, D., S. Salvi, D. Lienard, F. J. Lejeune, D. Speiser, L. Zografos and J. C. Cerottini (2003).
		Lack of BRAF mutations in uveal melanoma. Cancer Res 63(18): 5712-5.
19:	Rollini, P., S. Kaiser, E. Faes-Van't Hull, U. Kapp and S. Leyvraz (2003).
		Long-term expansion of transplantable human fetal liver hematopoietic stem cells. Blood. 2004 Feb 1;103(3):1166-70. Epub 2003 Sep 25
20:	Rossi, C. R., F. J. Lejeune, L. Pontes, M. Foletto, G. L. De Salvo, P. L. Pilati, S. Mocellin, M. Ribeiro, M. Lopes and M. Lise (2003).
		Phase I-II study on isolation antiblastic fotemustine perfusion after dacarbazine chemosensitization for advanced melanoma of the extremities. Melanoma Res 13(3): 293-7.
21:	Ruegg, C. and A. Mariotti (2003).
		Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis. Cell Mol Life Sci 60(6): 1135-57.
22:	Ruegg, C., J. Y. Meuwly, R. Driscoll, P. Werffeli, K. Zaman and R. Stupp (2003).
		The Quest for Surrogate Markers of Angiogenesis: A Paradigm for Translational Research in Tumor Angiogenesis and Anti-Angiogenesis Trials. Curr Top Med Chem 3(7): 673-691.
23:	Ruegg, C., J. Zaric and R. Stupp (2003).
		Non steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: hypes, hopes and reality. Ann Med 35(7): 476-87.
24:	Ruegg, C., O. Dormond and A. Mariotti (2003).
		Mediators and therapeutic targets of tumor angiogenesis. Biochim Biophys Acta Rev Cancer (in press).
25:	Ruegg, C., R. Driscoll, P. Wefferly-George and R. Stupp (2003).
		Translational research in tumor angiogenesis: from bench to bedside and back to the bench. Bull Suisse Cancer 23: 3-7.
26:	Rufer, N., A. Zippelius, P. Batard, M. J. Pittet, I. Kurth, P. Corthesy, J. C. Cerottini, S. Leyvraz, E. Roosnek, M. Nabholz and P. Romero (2003).
		Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood 102(5): 1779-87.
27:	Speiser, D. E., D. Rimoldi, P. Batard, D. Lienard, F. Lejeune, J. C. Cerottini and P. Romero (2003).
		Disease-driven T cell activation predicts immune responses to vaccination against melanoma. Cancer Immun 3: 12.
28:	Speiser, D. E., M. J. Pittet, D. Rimoldi, P. Guillaume, I. F. Luescher, D. Lienard, F. Lejeune, J. C. Cerottini and P. Romero (2003).
		Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. Semin Cancer Biol 13(6): 461-72.
29:	Stupp R, Hegi M.
		Recent developments in the management of maligant glioma. ASCO 2003 Educational Book. American Society of Clinical Oncologoly, Alexandria, VA, Perry MC {editor}. pp. 779-788, 2003.
30:	Stupp, R. and B. G. Baumert (2003).
		Promises and controversies in the management of low-grade glioma. Ann Oncol 14(12): 1695-6.
31:	Stupp, R. and R. e. C (2003).
		New drugs and combinations for malignant glioma. Forum (Genova) 13(1): 61-75.
32:	Stupp, R., R. C. Janzer, M. E. Hegi, J. G. Villemure and R. O. Mirimanoff (2003).
		Prognostic factors for low-grade gliomas. Semin Oncol 30(6 Suppl 19): 23-8.
33:	Valmori, D., V. Dutoit, M. Ayyoub, D. Rimoldi, P. Guillaume, D. Lienard, F. Lejeune, J. C. Cerottini, P. Romero and D. E. Speiser (2003).
		Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Cancer Immun 3: 15.
34:	Voelter, V., R. Stupp, M. Matter, M. Gillet, H. Bouzourene, S. Leyvraz and P. Coucke (2003).
		Preoperative hyperfractionated accelerated radiotherapy (HART) and concomitant CPT-11 in locally advanced rectal carcinoma: a phase I study. Int J Radiat Oncol Biol Phys 56(5): 1288-94.
35:	Vouillamoz-Lorenz, S., T. Buclin, F. Lejeune, J. Bauer, S. Leyvraz and L. A. Decosterd (2003).
		Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days. Anticancer Res 23(3C): 2757-65.
36:	Zouhair, A., D. Azria, P. Pasche, P. A. Coucke, R. Stupp, J. Chevalier, R. O. Mirimanoff and M. Ozsahin (2003).
		Accelerated postoperative radiation therapy with weekly concomitant boost in patients with advanced head and neck cancer. Int J Radiat Oncol Biol Phys 57(2 Suppl): S154-5.
37:	Zouhair, A., P. A. Coucke, D. Azria, P. Pache, R. Stupp, R. Moeckli, R. O. Mirimanoff and M. Ozsahin (2003).
		Prospective study of accelerated postoperative radiation therapy in patients with squamous-cell carcinoma of the head and neck. Cancer Radiother 7(4): 231-6.
38:	van den Bent, M. J., M. J. Taphoorn, A. A. Brandes, J. Menten, R. Stupp, M. Frenay, O. Chinot, J. M. Kros, C. C. van der Rijt, J. Vecht Ch, A. Allgeier and T. Gorlia (2003).
		Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 21(13): 2525-8.
39:	van den Bent, M. J., W. Grisold, D. Frappaz, R. Stupp, J. P. Desir, T. Lesimple, C. Dittrich, M. J. de Jonge, A. Brandes, M. Frenay, A. F. Carpentier, P. Chollet, J. Oliveira, B. Baron, D. Lacombe, M. Schuessler and P. Fumoleau (2003).
		European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. Ann Oncol 14(12): 1732-4.

Dernière modification le 10.06.2008